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In recent years, the Cre integrase from bacteriophage P1 has become an essential tool for conditional gene activation and/or
inactivation in mouse. In an earlier report, we described a fusion protein between Cre and a mutated form of the ligand
binding domain of the estrogen receptor (Cre-ERTM) that renders Cre activity tamoxifen (TM) inducible, allowing for
conditional modification of gene activity in the mammalian neural tube in utero. In the current work, we have generated
a transgenic mouse line in which Cre-ERTM is ubiquitously expressed to permit temporally regulated Cre-mediated
recombination in diverse tissues of the mouse at embryonic and adult stages. We demonstrate that a single, intraperitoneal
injection of TM into a pregnant mouse at 8.5 days postcoitum leads to detectable recombination in the developing embryo
within 6 h of injection and efficient recombination of a reporter gene in derivatives of all three germ layers within 24 h of
injection. In addition, by varying the dose of TM injected, the percentage of cells undergoing a recombination event in the
embryo can be controlled. Dose-dependent excision induced by TM was also possible in diverse tissues in the adult mouse,
including the central nervous system, and in cultured cells derived from the transgenic mouse line. This inducible Cre
system will be a broadly useful tool to modulate gene activity in mouse embryos, adults, and culture systems where
temporal control is an important consideration. © 2002 Elsevier Science (USA)
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The use of the P1 phage-derived integrase Cre to catalyze
recombination between its loxP target sites has revolution-
ized the analysis of gene function in the mouse (Nagy, 2000;
Rossant and McMahon, 1999; Rossant and Nagy, 1995).
One powerful use of this technology is in the conditional
removal or activation of gene function. In the former,
Cre-mediated recombination leads to the precise excision of
an essential region within a gene so that a functional
product is not produced. In the latter, Cre-mediated recom-
bination removes a functional barrier to the production of
an active gene product, thereby switching on gene activity.
One way in which the utility of this approach can be
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All rights reserved.enhanced is by developing ways in which Cre activity can
be controlled.
A number of groups have described various approaches to
controlling the spatial and/or temporal expression of the
enzyme (Gorman and Bullock, 2000; Nagy, 2000; Rossant
and McMahon, 1999). In one of these, a fusion gene is
created between Cre and a mutant form of the ligand-
binding domain of the estrogen receptor (ERTM). This mu-
tation prevents binding of its natural ligand (17-estradiol)
at normal physiological concentrations, but renders the
ERTM domain responsive to 4-hydroxy (OH)-TM (Danielian
et al., 1993; Fawell et al., 1990; Littlewood et al., 1995).
Fusion of Cre with ERTM leads to the ERTM-dependent
cytoplasmic sequestration of Cre by Hsp90 (Mattioni et al.,
1994; Picard, 1994), thereby preventing Cre-mediated re-
combination, a nuclear event. However, binding of
4OH-TM leads to a disruption of the interaction with3763. E-mail: amcmahon@mcb.harvard.edu.
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FIG. 1. Development of a TM-inducible gene modification system. (A) Potential use of CAGGCre-ERTM line to regulate gene activation
or inactivation in an embryo or postnatal animal. CAGGCre-ERTM line (line 1) can be used to excise DNA sequences flanked by two loxP
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Hsp90, permitting access of Cre-ERTM to the nucleus and
initiation of recombination.
We (Danielian et al., 1998) and others (Brocard et al.,
1997; Feil et al., 1996; Imai et al., 2001; Indra et al., 1999;
Schwenk et al., 1998; Vasioukhin et al., 1999; Vooijs et al.,
2001) have demonstrated tissue-specific manipulation of
gene activity by using transgenic Cre-ERTM lines. Impor-
tantly, these approaches have not been restricted to the
adult mouse: injection of TM into the pregnant animal has
been shown to activate recombination in the developing
sites (line 2). Excision in an embryo can be accomplished by injection of TM into a pregnant mother that carries double transgenic embryos
for lines 1 and 2. In postnatal animals, excision is achieved either ubiquitously by intraperitoneal injection of TM or within a specific target
organ by local injection of 4OH-TM. In this figure, an example of the local excision is shown. (B) Map of the pCAGGCre-ERTM construct.
Expression of Cre-ERTM is driven by a chimeric promoter/enhancer of the cytomegalovirus immediate-early enhancer and the chicken
-globin promoter/enhancer. The pCAGGs vector also contains an intron from chicken -globin and a polyadenylation signal from the
rabbit -globin.
FIG. 2. Efficient recombination in CAGGCre-ERTM; R26R mouse embryos following administration of TM at 8.5 dpc. Whole-mount views
of 9.5-dpc embryos following histochemical staining of embryos for -galactosidase activity. (A) Nontransgenic embryo. (B) CAGGCre-
ERTM; R26R compound transgenic embryo 24 h after corn oil injection. Note that there are some lacZ-positive cells in the absence of TM
induction (arrowhead in B). (C) CAGGCre-ERTM; R26R compound transgenic embryo 24 h after injection of 3 mg of TM (in corn oil)/40 g
of mother’s body weight induces widespread recombination. (D–F) Nomarski image of a 6-m section through the branchial arch region of
embryos in (A–C), respectively. In (E), cells displaying -galactosidase activity are indicated by the arrowhead.
FIG. 3. TM induces dose-dependent recombination in CAGGCre-ERTM; R26R mouse embryos. Compound transgenic embryos (CAG-
GCre-ERTM; R26R) were subjected to whole-mount histochemical staining for -galactosidase activity at 9.5 dpc, 24 h after administration
of the indicated dose of TM administration. (A) Whole-mount views of embryos. (B–E) Nomarski images of 6-m sections through embryos
in (A). (B) Sagittal view of embryo, (C) heart, (D) telencephalon, and (E) gut. Dose-dependent recombination was observed in tissue
derivatives of all three germ layers.
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embryo (Danielian et al., 1998; Kimmel et al., 2000; Vallier
et al., 2001). However, the tissue specificity of these lines,
while well suited to certain types of studies, limits the
general utility of these transgenic strains.
To create a more broadly useful strain of mouse, we set
out to generate a line in which Cre-ERTM is ubiquitously
expressed (Fig. 1A). In principle, crossing these mice to an
appropriate target strain (Fig. 1A) would permit TM-
dependent recombination in all tissues, with precise tem-
poral control, at embryonic and adult stages. We report a
line that exhibits widespread expression of Cre-ERTM and
demonstrate the utility of this strain in the control of
Cre-mediated genetic modification in embryonic and adult
mice and in cell culture.
EXPERIMENTAL METHODS
Generation of Construct
A fragment encoding Cre-ERTM (Danielian et al., 1998) was
cloned into pCAGGS vector (Niwa et al., 1991) to generate
pCAGGCre-ERTM. The ApaI site of pBS-Cre-ERTM was replaced by
an EcoRI site by using the oligo (CGAATTCGGGCC). An EcoRI
fragment containing Cre-ERTM was then subcloned into the EcoRI
site of pCAGGS. The orientation of the gene was confirmed by
sequencing.
Generation of Transgenic Animals
For pronuclear injection, pCAGGCre-ERTM was digested with
SalI and HindIII to remove vector sequences. The insert was
isolated by agarose gel electrophoresis and purified by electroelu-
tion, and then by using a PCR purification kit (Qiagen). The
purified DNA was resuspended in 10 mM Tris, pH 7.5, 0.1 mM
EDTA. The DNA concentration was determined by UV spectro-
photometry and the quality confirmed by agarose gel electrophore-
sis. Purified DNA was subjected to pronuclear injection by using a
standard method (Hogan et al., 1994). Potential founder animals
were screened by polymerase chain reaction (PCR) and further
confirmed by Southern blotting analysis. For PCR, mouse ear DNA
was amplified by 35 cycles on a thermal cycler using primers from
CAGGs (CTCTAGAGCCTCTGCTAACC) and Cre (CCTGGC-
GATCCCTGAACATGTCC) sequence. The size of the amplified
product is approximately 400 bp.
Cross-Breeding of Mice
Male CAGGCre-ERTM transgenics were crossed to females that
carried the Rosa reporter allele, R26R (Soriano, 1999). Offspring
were genotyped by PCR for CAGGCre-ERTM (as above) and R26R
alleles (Soriano, 1999), and males that carried both genetic modifi-
cations were crossed to Swiss-Webster (SW; Taconic) females to
obtain double transgenic embryos (at a predicted frequency of 1 in
4) for in utero studies.
Induction with TM or 4OH-TM
TM (Sigma) was dissolved in corn oil (Sigma) at a concentration
of 10 mg/ml. For the initial screening of the transgenic founders, 2
mg of TM was injected intraperitoneally into pregnant mothers at
embryonic day 10.5 (E10.5). Forty-eight hours later, embryos were
fixed and subjected to 5-bromo-4-chloro-3-indolyl-D-galactoside
(X-gal) staining as described below. For detailed characterization of
the Cre activity, 0.5, 1, 1.5, 2, 3, 6, or 9 mg of TM/40 g of body weight
was injected into pregnant mothers at 8.5 days postcoitum (dpc) and
embryos were harvested for 3, 6, 12, or 24 h postinjection and
subjected to histochemical staining to visualize -galactosidase activ-
ity. For analysis of adults, corn oil alone or 3 or 9 mg of TM/40 g of
body weight was injected intraperitoneally for 5 consecutive days.
Five days after the last injection, various organs from the mice were
fixed and subjected to X-gal staining. Single dose study was carried out
by injecting 9 mg of TM, and various organs were subjected to
histochemical staining 24 h or 5 days after the injection. Unless
specified otherwise, all injections of TM are per 40 g body weight.
4OH-TM (Sigma) was dissolved in ethanol to make a 1 mM stock
solution and further diluted to appropriate concentrations prior to use.
X-Gal Staining, Histology, and
Immunohistochemistry
Embryos collected at 9.5 dpc were stained postfixation in X-gal
for 3 h at 37°C (Whiting et al., 1991). Following X-gal staining,
embryos were refixed, dehydrated, embedded in paraffin, and
sectioned at 6 m. Adult mice were initially perfused with 2%
paraformaldehyde, and their organs were dissected and further
fixed overnight at 4°C. After washing with PBS several times,
organs were cryoprotected with 30% sucrose and embedded in
OCT compound (Tissue-Tek). Frozen sections were prepared at 12
m and subjected to X-gal staining. Immunostaining for Cre-ER
protein was carried out by using anti-Cre antibody (Ab) (Babco).
Frozen sections from embryos were prepared as described above,
then washed with PBS three times, blocked in PBS with 10% sheep
serum, 0.1% Triton X-100 for 1 h, and incubated overnight with
anti-Cre Ab (1:3000) at 4°C. Sections were washed three times with
PBS and the signal was detected by using anti-rabbit-Alexa 488
(Molecular Probes). Counterstaining was carried out by using DAPI
to visualize the nucleus. Images were obtained on a Zeiss confocal
microscope.
Induction of Recombination by 4OH-TM in
Primary Embryo Fibroblast (PEF) Cells and
Measurement of -Galactosidase Activity
PEF cells were obtained from 14.5-dpc embryos as described
(Hogan et al., 1994). Embryos were dissected individually and a
portion of the tail was used for PCR genotyping to identify
CAGGCre-ER; R26R embryos as described above. Cultured PEF
cells with the correct genotype were passaged once and used for
further experiments. Recombination was initiated by adding differ-
ent doses of 4OH-TM (Sigma) diluted in PEF media. At 6, 12, 24, or
48 h postinduction, PEF cells were subjected to either X-gal
staining as described above or an assay for -galactosidase activity
using a high sensitivity -galactosidase assay kit (Stratagene)
following the manufacturer’s protocol. The protein concentration
of the cell lysate was determined by a BCA protein assay system
(Pierce).
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RESULTS
Generation of CAGGCre-ERTM Transgenic Mice
To carry out temporally regulated activation or inactiva-
tion of gene activity, we sought to generate a transgenic
mouse line expressing Cre-ERTM (Fig. 1B) in a broad spec-
trum of cell types at embryonic and adult stages. The
promoter driving Cre-ERTM expression is a chimeric pro-
moter of the cytomegalovirus immediate-early enhancer
and chicken -actin promoter/enhancer (CAGG) that has
been shown to drive widespread expression of a number of
genes in transgenic mice (Lobe et al., 1999; Niwa et al.,
1991; Pratt et al., 2000). Pronuclear injection of the
CAGGCre-ERTM generated 33 founder transgenic animals
(generation [G]0). Of these, the 17 males were subjected to
an assay to verify the transmission of Cre recombination
activity into offspring by crossing to R26R reporter females
(Soriano, 1999). Pregnant mothers were injected with 2 mg
of TM at 10.5 dpc, embryos were collected 48 h later, and
-galactosidase activity was detected with X-gal. Four
founders failed to produce any X-gal-positive embryos. Ten
lines showed Cre recombinase activity restricted to the
heart, somites, and occasionally a portion of the central
nervous system (CNS) (data not shown). Two independent
lines (lines 3 and 5) generated embryos with -galactosidase
activity in most, if not all, cells (data not shown): one line
(line 37) showed patchy -galactosidase activity throughout
the embryo (data not shown). This frequency of obtaining
transgenic lines with ubiquitous expression utilizing the
CAGG regulatory sequences (2/17) is similar to a previous
report (Lobe et al., 1999). Analysis of lines 3 and 5 indicated
that the transgenic founders had multiple, independently
segregating integration sites. One of the sublines (line 5–8)
derived from G1 progeny of line 5, did not show any further
segregation of the transgene insertion and maintained the
founder’s TM-inducible recombination activity (data not
shown). Line 5–8 was chosen for further study.
Efficient Cre-Mediated Recombination Induced by
TM in Diverse Tissues of the Mouse Embryo
To test the efficiency of TM-dependent Cre recombinase
activity in mouse embryos, we focused our analysis at 8.5
dpc. At this time, the three germ layers of the mouse
embryo have undergone initial patterning with respect to
the major body axes, but most organ systems are not
established. Initially, we performed a dose toxicity analysis
following a single intraperitoneal injection of TM into
nontransgenic SW or B6CBAF1 females at 8.5 dpc. An
injection of 3 mg/40 g body weight allowed normal devel-
opment to term of most embryos (30/48). In contrast,
embryos developing in pregnant females injected with
higher concentrations (6 and 9 mg/40 g body weight) failed
to develop to term, although most embryos were viable at
13.5 dpc (26/36 and 28/44, respectively). The dose toxicities
were similar in both strains (data not shown). When these
same doses were administered at 11.5 and 14.5 dpc, a good
survival frequency to term was observed (6 mg, 33/42 and
36/40, respectively; 9 mg, 21/48 and 30/39, respectively).
Importantly, dose toxicity does not appear to show a simple
linear correlation with body weight; embryos developing in
high mass females (40 g or greater) are able to tolerate
higher doses of TM better than those in lower mass females.
In initial studies, CAGGCre-ERTM; R26R males were
mated to SW females and pregnant females were injected at
8.5 dpc with either corn oil or corn oil supplemented with
3 mg TM/40 g of body weight. Embryos were collected 24 h
later and analyzed in whole mount for -galactosidase
activity. No -galactosidase activity was detected in em-
bryos lacking the R26R transgene (Figs. 2A and 2D) or
following corn oil injection (data not shown). Analysis of
CAGGCre- ERTM; R26R embryos detected a low percentage
of cells (estimated at less than 0.1%) that underwent
spontaneous, sporadic recombination in the absence of TM
(Figs. 2B and 2E). However, 3 mg of TM induced widespread
recombination throughout the embryo within 24 h (Fig.
2C). Analysis of tissue sections indicated that greater than
50% of cells expressed the transgenic reporter, indicating
FIG. 4. Intracellular localization of Cre-ER protein following TM injection. Cre-ER protein was detected by using an anti-Cre antibody
(D–F) in CAGGCre-ER embryos at 24 (E), or 48 h (F) postinjection (pi), of 3 mg TM. As an uninduced control, embryos were obtained from
the mother injected with corn oil (D). Nuclei were visualized by DAPI (G–I). Initial blue color for DAPI staining was converted to green by
Adobe Photoshop by maintaining the intensity intact to have better clarity for the level of colocalization. Merged pictures of two were
shown in (A), (B), and (C), respectively. Note that without TM, Cre-ER protein is broadly distributed in cell (A, D, and G), but 24 h after
injection of 3 mg TM, Cre-ER protein strongly localizes in nuclei (E). At 48 h postinjection, significant nuclear localization has almost
disappeared (C, F, and I).
FIG. 5. The dynamic dose-related response to TM in CAGGCre-ERTM; R26R mouse embryos. Compound transgenic embryos (CAGGCre-
ERTM; R26R) were subjected to whole-mount histochemical staining for -galactosidase activity 6 (A, C) or 12 (B, D) h after administration
of 3 (A, B) or 6 (C, D) mg of TM by intraperitoneal injection into the pregnant female. At 6 h postinjection (pi) of 3 mg/40 g body mass,
TM-injected embryos showed very weak -galactosidase activity (A), whereas embryos receiving 6 mg showed both a higher level of enzyme
activity on the average and more cells with detectable activity (compare B with A and Fig. 2). At both concentrations, there was a significant
increase in the recombination frequency 12 h postinjection, but recombination was significantly less than that observed 24 h postinjection
(compare B and D with Fig. 2C).
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that TM induced a rapid, efficient recombination (Fig. 2F;
and data not shown).
Dose-Dependent Recombination of CAGGCre-ERTM
by TM in the Mouse Embryo
To evaluate the dose dependency of Cre recombinase
activity in mouse embryos and the activity in different
germ layer derivatives, the aforementioned protocol was
followed with pregnant females receiving different doses of
TM (0.5, 1, 1.5, 2, 3, 6, or 9 mg per 40 g of body weight). At
all doses tested, TM-induced recombination was greater
than the background recombination observed in CAGGCre-
ERTM; R26R embryos (compare Figs. 2B and 3A). Whole-
mount visualization of embryos indicated a dose-dependent
increase in the recombination efficiency in response to TM
injections ranging from 0.5 to 3.0 mg with no apparent
increase above 3 mg (Fig. 3A). Analysis of sectioned mate-
rial revealed that recombination was observed in all germ-
layer derivatives (heart, brain, surface ectoderm, and gut;
Figs. 3B–3E), demonstrating the widespread expression of
the CAGGCre-ERTM transgene. The sectioned material also
revealed a dose-dependent increase in the frequency of
recombination 24 h postinjection up to the maximum dose
of 9 mg of TM (Figs. 3B–3E). For example, in the telenceph-
alon of embryos induced by a 3 mg injection of TM,
approximately 75% of cells showed -galactosidase activ-
ity, the percentage increasing to 85% of cells following a
9-mg injection. In addition, the proportion of cells within a
tissue that showed weaker -galactosidase activity, pre-
sumably reflecting a more recent recombination event than
neighboring cells that display high levels of enzyme activ-
ity, decreased following an injection of 9 mg of TM. Thus,
increasing the dose of TM from 3 to 9 mg results in a more
rapid (high levels of enzyme activity in cells) and more
efficient (ratio of recombined to nonrecombined cells [blue
to white]) induction of recombination. Even so, a small
percentage of cells in all tissues (estimated at less than
20%) failed to undergo recombination within 24 h of TM
administration. However, when we examined embryos at
48 h postinjection, we observed a higher rate of recombina-
tion (95% in the telencephalon following a 3-mg injection
at 8.5 dpc), indicating that the drug is present at effective
concentrations beyond 24 h postinjection.
To attempt to address more directly the issue of how long
Cre-ERTM remains active, we examined the subcellular
distribution of Cre-ERTM protein within embryonic tissues.
We observed a significant nuclear accumulation of Cre-
ERTM within 24 h of TM injection, which was dramatically
reduced 48 h postinjection (Fig. 4). Thus, it is likely that the
majority of Cre-ERTM activity is lost within 48 h of a single
3 mg/40 g injection of TM at 8.5 dpc, though it would
require the introduction of a second reporter construct at
these later stages to rigorously address this issue.
Next, we investigated how rapidly reporter gene expres-
sion could be detected within the embryo following injec-
tion of a single dose of TM (3 or 6 mg/40 g) at 8.5 dpc.
Embryos were collected at 3, 6, and 12 h and -galactosidase
activity was assessed histochemically (Fig. 5; and data not
shown). Enzyme activity was not detected 3 h postinjec-
tion, but low levels of activity were detected at 6 h, with
slightly higher levels of activity in embryos receiving the
higher dose of TM. Both the levels of -galactosidase
activity within cells and the number of cells with detect-
able enzyme activity markedly increased from 6 to 12 h
postinjection (Fig. 5). Thus, recombination is initiated rap-
idly within the embryo, but it is likely that prolonged
access to the drug is essential for high levels of recombina-
tion to be achieved.
Much of the analysis of this system has deliberately
centered around 8.5 dpc as a time prior to the establishment
of a functional placental connection when organogenesis
and patterning of important tissues (for example, the neural
tube) are initiating. To provide some additional insight into
the effectiveness of TM-induced recombination at later
stages of in utero development, single intraperitoneal injec-
tions of TM (3 and 9 mg) were administered at 11.5 and 14.5
dpc, and embryos were assessed by histochemical staining
for -galactosidase activity 24 h postinjection. As at earlier
stages, widespread recombination was observed. At the
lower dose, approximately 50–60% of cells underwent a
detectable recombination event; this figure increased to
60–70% at the higher concentration (data not shown).
Thus, this system provides a rapid, effective means by
which gene activity can be modulated in the developing
embryo at multiple stages of postimplantation develop-
ment.
Induction of Cre Activity in Adult Mice
To test the potential use of the CAGGCre-ERTM line in
adult tissues, the recombination efficiency was examined
following intraperitoneal injection of TM into 12-week-old
animals. Organs were harvested from mice 5 days after 5
consecutive days of injection of 0, 3, or 9 mg of TM.
Multiple injections of even the highest dose did not lead to
FIG. 6. Dose-dependent recombination in adult CAGGCre-ERTM; R26R mice. Adult compound transgenic animals (CAGGCre-ERTM;
R26R) were injected once a day for 5 consecutive days with either corn oil alone or corn oil containing 3 or 9 mg of TM per 40 g body mass,
as indicated. Frozen sections through various organs were assayed by histochemistry for -galactosidase activity 5 days after the final
injection. Nomarski views of (A) cerebral cortex, (B) cerebellum, (C) heart, (D) kidney, (E) lung, and (F) liver. Note that strong
dose-dependent induction of recombination by TM was observed in the brain, heart, kidney, and lung. Only low levels of recombination
are evident in the liver.
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any obvious change in the behavior, feeding, or appearance
of the mice over the period of study. As expected from the
slight “leakiness” of Cre-ERTM activity that was observed at
embryonic stages, -galactosidase activity was detected in
some cells in the absence of TM injection: however, the
proportion of these cells remained low, indicating the tight
regulation of Cre activity over many weeks and many
rounds of cell division. Efficient dose-dependent recombi-
nation was observed in most organs, including the cortex
(Fig. 6A), cerebellum (Fig. 6B), and hippocampus in the brain
(data not shown), heart (Fig. 6C), kidney (Fig. 6D), lung (Fig.
6E), pancreas, and intestine (data not shown). In all cases,
recombination was observed in a broad range of cell types.
In contrast, the liver displayed a highly mosaic pattern of
recombination that was dose-dependent as in the other
organs (Fig. 6F). This mosaic pattern of recombination is not
due to a problem in reporter expression within the liver, as
the locus is expressed ubiquitously in this tissue (data not
shown). These results indicate that the transgenic line
allows efficient manipulation of gene activity in many, but
not all, organs. To address how rapidly recombination is
detected in adult tissues, we assayed -galactosidase activ-
ity in a variety of tissues 24 h after a single, intraperitoneal
injection of 9 mg of TM injection into an adult (40 g) mouse
(Fig. 7). Although recombination was detected in many
tissues, recombination was highly mosaic, being most
readily detected in highly vascular tissue (e.g., the heart).
Thus, either a single dose, or a 24-h period postinjection is
not sufficient to lead to as widespread a modification of
gene activity, as was observed following the multiple injec-
tion scheme discussed earlier. To determine whether this
simply reflected the period of exposure to the drug, we also
examined tissues 5 days postinjection (Fig. 7). An increase
in recombination was observed in some tissues (cortex and
kidney; Fig. 7), but generally lower levels of recombination
were observed in most tissues when compared with mul-
tiple administrations of TM (Fig. 6).
Dose-Dependent Recombination in Cultured PEF
Cells
As an alternative to the manipulation of gene activity in
the whole organism, we investigated the ability of 4OH-TM
to modulate recombination in cell cultures derived from
14.5-dpc embryos. Fibroblast cultures were prepared and
recombination assayed 24–48 h following the addition of
varying concentrations (10 pM to 1 M) of 4OH-TM. All
doses resulted in a small increase in activity over 24 h (4- to
5-fold) and a large increase 48 h (13- to 27-fold) after the
initiation of drug treatment (Fig. 8A). The large increase in
activity correlated with a substantial increase in the num-
ber of cells displaying -galactosidase activity (Fig. 8B).
Indeed, 75% of all cells underwent a recombination event
within 48 h in response to the lowest dose of TM tested (10
pM; Fig. 8B), and this number increased to over 90% at the
highest concentration (1 M; Fig. 8B). Thus, the CAGGCre-
ERTM line is an effective tool for manipulating gene activity
in either the organism or in cell culture.
DISCUSSION
Dose-Dependent Recombination of CAGGCre-ERTM
We have generated a transgenic mouse line that exhibits
widespread expression of a TM-inducible Cre transgene:
addition of TM or its derivative 4OH-TM results in effi-
cient, dose-dependent recombination in embryos develop-
ing in utero, in adult mice, and in cell culture. A recent
report (Vooijs et al., 2001) describes a similar approach in
which a Cre-ERTM transgene was “knocked-into” the
ROSA26 locus. These authors demonstrated effective re-
combination in a variety of adult tissues as monitored by
Southern analysis of whole tissue extracts 7 days after a
multiple round of TM injection as we report with the
CAGGCre-ERTM transgene. However, Vooijs et al. (2001)
did not address the effectiveness of their line for in utero
modification of gene activity. Thus, a strict comparison of
the relative effectiveness of each strain in a similar analysis
is not possible at this time, but the general availability of
two independent strains that affect the temporal modifica-
tion of gene activity will be a valuable asset to the research
community.
Given our own interests, we have focused for the most
part on embryos between 8.5 and 9.5 dpc, when initial
patterning events have established the general organization
of the body plan, but coincident with, or just prior to, the
establishment of most of the organ primordia. In an earlier
study in which expression of the same transgene was
restricted to the neural tube under the control of a Wnt1
regulatory element, we failed to observe efficient recombi-
nation during this particular period. However, efficient
recombination was observed after the establishment of an
embryonic/maternal circulation 1 day later (Danielian et
al., 1998). The current work indicates that establishment of
a circulatory connection is not essential and that the
absence of recombination in the Wnt1 model most likely
reflects a lower level of expression of the Cre transgene
under Wnt1 control or a changes in the dosing scheme
adopted here.
The CAGGCre-ERTM line displayed dose-dependent re-
combination between 0.5 and 9 mg of TM, with higher
doses giving higher degrees of recombination. However, the
recombination efficiency has to be weighed against the
lethality (presumably due to a disruption of maternal–fetal
interactions at high concentrations of the estrogen-like
steroid) that results from administration of high concentra-
tions of TM (Sadek and Bell, 1996). In this study, we focused
on animals of a particular body weight (40 g) because of
preliminary evidence that the toxic effects of TM concen-
tration on embryonic development did not follow a simple
linear progression with increasing body mass of the preg-
nant mouse. Little toxicity was observed following injec-
tion of 2 mg or less: however, significant lethality was
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FIG. 8. 4OH-TM induces efficient recombination in cultured primary embryo fibroblasts (PEF). PEF cells were isolated from 14.5-dpc
compound transgenic embryos (CAGGCre-ERTM; R26R) and treated with different doses of 4OH-TM as indicated, and the -galactosidase
activity was determined by using a biochemical assay of cell lysates (A) or by direct counting of cells after histochemical detection (B). Each
point is the mean of triplicate measurements with the standard deviations indicated by the error bars. (C) Nomarski views of the
histochemical detection of -galactosidase activity in cells following treatment with 0 or 10 pM or 1 M 4OH-TM for 24 or 48 h.
FIG. 7. Recombination efficiency following a single injection of TM into adult mice. Adult compound transgenic animals (CAGGCre-
ERTM; R26R) were injected with 9 mg of TM per 40 g of body mass. One day or 5 days postinjection (pi), a variety of organs were harvested,
frozen sections were prepared, and this material was subjected to histochemistry to assess -galactosidase activity. Nomarski views of (A)
cerebral cortex, (B) cerebellum, (C) heart, (D) kidney, (E) lung, and (F) liver.
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observed following injection of 3–9 mg. At 3 mg, a dose that
leads to over 50% of cells undergoing a recombination
event 24 h post injection, most embryos will survive to
term, though a cesarean section is required for delivery. In
contrast, most embryos developing in females receiving 6 or
9 mg of TM survive to 13.5 dpc, but none survived to term.
At this dose, up to 80% of cells within a tissue underwent
recombination within 24 h of TM injection. Consequently,
if rapid, efficient recombination was required to study the
properties of a particular gene in a narrow time interval
following the recombination-mediated genetic modifica-
tion, injection of the highest doses would seem to be a
reasonable strategy. If, in contrast, later survival is impor-
tant, injection of 3 mg of TM per 40 g of body weight would
appear to be the best option. It should be noted that our
measure of recombination is the presence of -galactosidase
activity. This requires transcription and translation of the
reporter allele following the recombination event. Conse-
quently, the actual recombination frequency at the DNA
level at any time is likely to be higher. Further, if one
examines the intensity of histochemical staining of cells
displaying -galactosidase activity, it is evident that the
ratio of cells exhibiting weak versus strong activity de-
creases as the TM injection dosage is increased from 3 to 9
mg. The most likely explanation is that weak activity
reflects a more recent recombination event and conse-
quently -galactosidase levels are not maximal in the cell.
Indeed, consistent with this view, embryos harvested at
48 h postinjection of 3 mg of TM displayed a higher
percentage of cells (95%) exhibiting detectable
-galactosidase levels. The reduction in nuclear localized
Cre-ER protein 48 h after the injection of 3 mg of TM
suggests that further recombination is less likely beyond
this time point. Finally, the recombination-inducing activ-
ity and developmental toxicity of a specific dosage are
likely to vary at different stages of pregnancy. A thorough
investigation of responses at different stages awaits further
study, but our results indicate that injection of 3 mg at 10.5
dpc leads to complete recombination in most tissues by
12.5 dpc and that administration of the highest dose of TM
at 11.5 and 14.5 dpc induces a robust recombination in
many tissues within 24 h (greater than 50%). Further,
injection of the highest dose (9 mg) is compatible with
survival to term.
As a further demonstration of the utility of this line, we
showed that multiple rounds of intraperitoneal injection of
TM (3 mg/day for 5 days) resulted in efficient induction of
recombination in a broad spectrum of adult tissues, includ-
ing the brain, indicating that the blood–brain barrier does
not prevent access of the drug. Clearly not all tissues
respond equally well; for example, although the liver ex-
presses the ROSA26 reporter quite strongly in control
experiments, we observe only patchy activity following TM
injection, indicating very poor levels of recombination. It is
unlikely that this reflects a problem in the accessibility of
the drug to this tissue as the liver actually converts TM to
4OH-TM, the actual steroid that binds in vivo to the
mutated ER domain (Littlewood et al., 1995; Williams et
al., 1994). A more likely possibility is varying levels of
CAGGCre-ERTM expression in adult tissues, though this
remains to be determined.
Potential Use of CAGGCre-ERTM
With the adjustment of TM dose to balance recombina-
tion efficiency versus toxicity, this line could be particu-
larly useful in controlling gene activity in a temporally
regulated fashion. For example, if some essential sequence
within a gene is flanked by two loxP sites (gene A in Fig.
1A), TM administration can be used to remove activity of
this gene at a certain stage of embryonic or postpartum
development. Alternatively, if the sequence following the
second loxP site encodes a functional gene (gene B in Fig.
1A), this protocol would allow conditional activation of the
gene. This approach should allow researchers to circumvent
problems associated with germ-line ablation and early em-
bryonic lethality caused by a standard knockout or overex-
pression approaches, thereby allowing a more complete
analysis of gene function.
Clearly, widespread expression of the transgene will
ensure a general removal or activation of a given gene in a
broad spectrum of tissues at a given stage of development.
In many circumstances, having a precise temporal control
of the recombination event will circumvent the problem of
genes that may have unique activities in different tissues at
different stages of development. However, the situation is
more complex when the given gene may play several
different roles at the same stage of development. Here,
tissue-specific removal of gene activity using tissue-specific
transgenic Cre lines provides a complementary tool.
Clearly, the combination of tissue-specific regulatory ele-
ment and Cre-ERTM provides a valuable alternative for the
dissection of sequential actions of a gene within a given
tissue.
By controlling the site of drug delivery, the CAGGCre-
ERTM transgene may also allow spatial modulation of gene
activity. Local injection of 4OH-TM has been shown to
activate other forms of TM-inducible Cre (Feil et al., 1997;
Vooijs et al., 2001; Indra et al., 1999; Vasioukhin et al.,
1999), providing a spatial restricted response. Further, if
combined with the previously developed techniques of
ultrasound backscatter microscopy (UBM), which allows
visualization of embryos in utero (Gaiano et al., 1999), or
stereotaxic injection, the potential application of this line
could be greatly broadened.
The demonstration that cells can be removed from CAG-
GCre-ERTM; R26R embryos and their genetic activity ma-
nipulated in cell culture suggests a number of approaches.
For example, new cell lines can be created directly from
embryonic or adult tissues of a particular genetic make-up
in which the presence of CAGGCre-ERTM will enable the in
vitro manipulation of gene activity in the precise study of a
particular cellular action. In vitro explants also provide
another means by which the response may be localized to a
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given tissue or organ at a specific stage of development.
Finally, by culturing preimplantation embryos in the pres-
ence of 4OH-TM, it may be possible to generate large
numbers of embryos in which gene activity is modified at
an early stage.
The fact that CAGGCre-ERTM induces dose-dependent
recombination suggests a potential use of this line in the
generation of genetic mosaic animals, an extremely valu-
able research tool in the study of invertebrate model sys-
tems. Low doses of TM induce recombination in a small
fraction of cells. By regulating the dose of TM, one could
generate different levels of mosaicism. With a means to
identify cells that have undergone the recombination event,
the properties of these cells can be investigated and com-
pared with wild-type neighbors. Further, it may be possible
to generate a phenotypic series if the levels of a certain
factor can be controlled by altering the numbers of cells
that express that factor. Generation of genetic mosaics is
also a generally useful technique to study the function of
genes, when ablation or overexpression of these genes
causes lethality. Use of the CAGGCre-ERTM mouse will
provide a complementary approach to more classical chi-
meric experiments that use genetically distinct embryo/
embryo or embryo/ES cell chimeras (Nagy and Rossant,
2001).
Another potential application of the pCAGGCre-ERTM
line is for clonal analysis. The key to this approach is that
recombination should occur very infrequently so that two
cells that share reporter gene expression lying close to one
another are more likely to represent clonal relatives than
independent recombination events. Others have used rare
mitotic recombination events to label cells (Bonnerot and
Nicolas, 1993; Mathis et al., 1997; Sanes, 1994). The TM-
independent leaky recombination we observe may provide
an alternative approach. This recombination event clearly
occurs relatively late in development, as evidenced by the
small number of cells displaying -galactosidase activity at
9.5 dpc (less than 0.1%) and later stages, and their sporadic
distribution which varies from embryo to embryo. Interest-
ingly, despite the low frequency of marked cells, many are
clustered, suggesting that they are clonally related (see Fig.
2B). Further, during the screening of CAGGCre-ERTM
founders, we identified a second transgenic line (line 37)
which showed a highly patchy distribution of cells with
-galactosidase activity scattered throughout the embryo
following TM injection (data not shown). Modulating the
activity of this line with different TM concentrations may
allow clonal analysis to be optimized.
Although genetic studies in the mouse have played a
major role in dissecting developmental pathways, their
potential for addressing issues of physiology in the adult
mouse have yet to be fully realized. Clearly, one important
reason for this is that many genes that regulate the adult
physiological state also have essential functions during
embryonic development precluding the generation of adult
mutants without conditional gene-removal strategies. One
particularly valuable role that this transgene will play is in
genetic modification in the adult mouse. Although it may
not be possible to induce complete recombination, recom-
bination frequencies for most tissues are very high with the
dosing schedule we describe. This should enable the iden-
tification of new modulators of adult physiology and the
generation of valuable disease models for the study of adult
pathologies, including cancer. Finally, although not elabo-
rated here, the CAGGCre-ERTM line should be useful in all
systems where the enzymatic activity of Cre at target lox P
sites has previously been applied to manipulating inversion,
integration, and translocation of chromosomes (Nagy,
2000). In summary, the approach we describe will be a
valuable new tool in dissecting the mechanisms underlying
developmental, physiological, and pathological processes.
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